Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3–7 of the Aβ peptide. Aducanumab discriminates between monomer...

Descripción completa

Detalles Bibliográficos
Autores principales: Arndt, Joseph W., Qian, Fang, Smith, Benjamin A., Quan, Chao, Kilambi, Krishna Praneeth, Bush, Martin W., Walz, Thomas, Pepinsky, R. Blake, Bussière, Thierry, Hamann, Stefan, Cameron, Thomas O., Weinreb, Paul H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913127/
https://www.ncbi.nlm.nih.gov/pubmed/29686315
http://dx.doi.org/10.1038/s41598-018-24501-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913127/
https://www.ncbi.nlm.nih.gov/pubmed/29686315
http://dx.doi.org/10.1038/s41598-018-24501-0

Ejemplares similares